Results 51 to 60 of about 1,077,721 (136)
ABSTRACT Objective This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti‐inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices,
José Norberto Vásquez‐Bonilla
wiley +1 more source
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy
International drug policy is rapidly evolving in tandem with promising evidence for psychedelic-assisted psychotherapy (PAP) in treating a range of mental health conditions.
Victor Mocanu +3 more
doaj +1 more source
Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review
ABSTRACT Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes.
Lucas Cruz +4 more
wiley +1 more source
Long‐Term Therapy Experiences in Post‐suicidal Men: Safety, Gender and Iatrogenic Harm
Men who have survived a suicide attempt and engaged in long‐term psychotherapy describe the therapeutic relationship as the primary agent of recovery—not technique, but sustained relational presence. Gender dynamics, developmental history and institutional failure all shape engagement. These findings challenge short‐term service models and carry direct
Alastair Coomes, Joel Vos, Ron Roberts
wiley +1 more source
Psychedelic research became throttled in the 1970s, though the clinical interest for psychedelics has seen a resurgence in the last couple of decades for their application as psychotherapy-adjunct substances used to treat various psychological disorders.
Johansson, Andreas
core +3 more sources
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le +8 more
wiley +1 more source
The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? [PDF]
Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches.
Trevor R. Norman
doaj +1 more source
Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović +4 more
wiley +1 more source
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
Psilocybin as a novel treatment for chronic pain
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source

